Home
Diseases
Shortness of Breath

Shortness of Breath

Disease

Related News

Milestone Pharmaceuticals' CARDAMYST Nasal Spray Gains Express Scripts Formulary Access

Apr 01, 2026

Express Scripts has added Milestone Pharmaceuticals' CARDAMYST nasal spray to its national formularies, improving access to the first FDA-approved self-administered treatment for PSVT in 30 years. The drug was approved in December 2025 and clinical studies show it converts PSVT episodes twice as likely and three times faster than placebo. The company has also submitted a marketing application to European regulators.

Mavacamten Shows Promise for Adolescents with Hypertrophic Cardiomyopathy

Mar 30, 2026

Mavacamten significantly reduces heart obstruction in adolescents with hypertrophic cardiomyopathy, with patients experiencing a 48.5 mm Hg drop in blockage compared to minimal change in placebo groups. The drug also lowered blood markers indicating heart damage and showed promise in slowing disease progression. Separate real-world data confirms mavacamten's effectiveness as monotherapy across diverse patient populations.

FDA Accepts Savara's MOLBREEVI Application for Autoimmune PAP with Priority Review

Feb 21, 2026

Savara Inc. announced the FDA has filed for review the BLA for MOLBREEVI to treat autoimmune PAP, granting Priority Review with a PDUFA action date of August 22, 2026. The therapy could become the first approved treatment for this rare lung disease.

European Commission Approves MYQORZO for Obstructive Hypertrophic Cardiomyopathy

Feb 17, 2026

The European Commission approved MYQORZO (aficamten) for treating symptomatic obstructive hypertrophic cardiomyopathy in adults, completing global regulatory approvals following FDA and China NMPA clearances. First European launch planned in Germany in Q2 2026.

Scientists Identify Immune Mutation Behind Rare Blood Clots From Adenovirus COVID Vaccines

Feb 12, 2026

International researchers have identified a specific antibody mutation that causes rare but serious blood clots after adenovirus-based COVID-19 vaccines or natural adenovirus infection, providing a roadmap for safer vaccine design.

Related Clinical Trials

NCT ID	Title	Status	Phase
NCT07452731	Effectiveness of a Mastery Learning Education Program for Parents of Children Using Inhaler Therapy in an Emergency Unit	RECRUITING	NA
NCT07182955	Determinants of Cardiorespiratory Fitness and Effects of HIIT in Patients With ANOCA Obstructive Coronary Artery Disease(ANOCA)	RECRUITING	NA
NCT07128511	Training Strategies to Maintain Performance	NOT_YET_RECRUITING	NA
NCT06927973	Leveraging Exercise Stress Echocardiography for Heart Failure With Preserved Ejection Fraction	COMPLETED	NA
NCT06554353	Cardiopulmonary Exercise Testing and Oscillometry for the Evaluation of Dyspnea	RECRUITING
NCT06463288	Comparison of Jacobson Relaxation Technique and Pranayama Technique in Patients With COPD	COMPLETED	NA
NCT06201494	Prospective Multicentre Study on Symptoms in First-onset Bronchial Asthma in Children and Adolescents	RECRUITING
NCT06196957	Effect of Senobi Versus Buteyko Technique on Functional Performance of Chronic Obstructive Pulmonary Disease Patient.	COMPLETED	NA
NCT05992324	A Validation Study to Evaluate the Performance of Caption Health Lung Guidance and Interpretation	RECRUITING	NA
NCT05812209	Stellate Ganglion Block to Treat Long COVID 19 Case Series	COMPLETED